EMMA CROCAMO: Open Payments
NPI 1881309979 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$901 in 30 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $867 · 2025 $901
Food & beverage: $888Education: $12
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 3 | $242 |
| ABBVIE INC. | 7 | $222 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| PFIZER INC. | 3 | $67 |
| Gilead Sciences, Inc. | 3 | $58 |
| Regeneron Healthcare Solutions, Inc. | 1 | $35 |
| QOL Medical, LLC | 1 | $32 |
| Lilly USA, LLC | 1 | $31 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| Janssen Biotech, Inc. | 1 | $24 |
Products named: REZDIFFRA, XELJANZ, RINVOQ, ENTYVIO, DUPIXENT, Sucraid, ZEPBOUND, REBYOTA.
Industry payments across MA — which companies pay providers there.
